
|Videos|October 15, 2017
Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Author(s)Contagion® Editorial Staff
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
Advertisement
Magda Opsomer, MD, director and clinical leader of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, Belgium, reveals who will benefit from the darunavir single-tablet HIV regimen.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
House Lawmakers Probe FDA Over COVID-19 Vaccine Death Claims and Proposed Vaccine Regulation Changes
2
FDA Grants First Approval Under Priority Voucher Program, Fast-Tracking Antibiotic to Strengthen US Drug Supply Chain
3
ACIP Votes on Hepatitis B Vaccine Marks More Confusion, No Supportive Safety Data, and Uncertainty of Public Health Policy
4
Opioid Use Linked to Nearly Double the Risk of C difficile Infection
5


















































































































































































































































































